德琪医药-B绩后拉升逾20%,截至发稿,股价上涨15.43%,现报4.04港元,成交额1884.80万港元。3月21日,德琪医药-B发布截至2024年12月31日止年度业绩,该集团取得收入人民币9195万元(单位下同),同比增加36.62%;研发开支2.59亿元,同比减少36.18%;年内亏损3.19亿元,同比减少45.07%;经调整年内亏损3.05亿元,同比减少42.95%;每股亏损0.51元。...
Source Link德琪医药-B绩后拉升逾20%,截至发稿,股价上涨15.43%,现报4.04港元,成交额1884.80万港元。3月21日,德琪医药-B发布截至2024年12月31日止年度业绩,该集团取得收入人民币9195万元(单位下同),同比增加36.62%;研发开支2.59亿元,同比减少36.18%;年内亏损3.19亿元,同比减少45.07%;经调整年内亏损3.05亿元,同比减少42.95%;每股亏损0.51元。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.